Arab Drug Past Earnings Performance
Past criteria checks 1/6
Arab Drug has been growing earnings at an average annual rate of 5.5%, while the Pharmaceuticals industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 8.3% per year. Arab Drug's return on equity is 23.1%, and it has net margins of 10.3%.
Key information
5.5%
Earnings growth rate
11.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 8.3% |
| Return on equity | 23.1% |
| Net Margin | 10.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Arab Drug makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 723 | 74 | 97 | 0 |
| 30 Sep 23 | 671 | 62 | 94 | 0 |
| 30 Jun 23 | 634 | 71 | 99 | 0 |
| 31 Dec 22 | 549 | 80 | 91 | 0 |
| 30 Sep 22 | 515 | 78 | 84 | 0 |
| 30 Jun 22 | 505 | 76 | 81 | 0 |
| 31 Dec 21 | 526 | 93 | 82 | 0 |
| 30 Sep 21 | 532 | 96 | 83 | 0 |
| 30 Jun 21 | 537 | 101 | 82 | 0 |
| 31 Mar 21 | 527 | 104 | 76 | 0 |
| 31 Dec 20 | 540 | 106 | 76 | 0 |
| 30 Sep 20 | 544 | 106 | 75 | 0 |
| 30 Jun 20 | 521 | 93 | 73 | 0 |
| 31 Mar 20 | 524 | 82 | 75 | 0 |
| 31 Dec 19 | 494 | 66 | 71 | 0 |
| 30 Sep 19 | 456 | 52 | 69 | 0 |
| 30 Jun 19 | 436 | 43 | 66 | 0 |
| 31 Mar 19 | 415 | 43 | 90 | 0 |
| 31 Dec 18 | 403 | 43 | 91 | 0 |
| 30 Sep 18 | 401 | 42 | 68 | 0 |
| 30 Jun 18 | 383 | 39 | 60 | 0 |
| 31 Mar 18 | 379 | 45 | 20 | 0 |
| 31 Dec 17 | 371 | 43 | 9 | 0 |
| 30 Sep 17 | 358 | 39 | 23 | 0 |
| 30 Jun 17 | 339 | 35 | 22 | 0 |
| 31 Mar 17 | 315 | 28 | 24 | 0 |
| 31 Dec 16 | 290 | 22 | 24 | 0 |
| 30 Sep 16 | 262 | 17 | 25 | 0 |
| 30 Jun 16 | 250 | 14 | 25 | 0 |
| 31 Mar 16 | 240 | 6 | 24 | 0 |
| 31 Dec 15 | 231 | 5 | 23 | 0 |
| 30 Sep 15 | 225 | 5 | 22 | 0 |
| 30 Jun 15 | 224 | 5 | 22 | 0 |
| 31 Mar 15 | 223 | 3 | 23 | 0 |
| 31 Dec 14 | 220 | 3 | 23 | 0 |
| 30 Sep 14 | 215 | 4 | 21 | 0 |
| 30 Jun 14 | 206 | 3 | 20 | 0 |
| 31 Mar 14 | 194 | 3 | 18 | 0 |
| 31 Dec 13 | 184 | 1 | 18 | 0 |
| 30 Sep 13 | 176 | 0 | 18 | 0 |
| 30 Jun 13 | 172 | 0 | 17 | 0 |
Quality Earnings: ADCI has a high level of non-cash earnings.
Growing Profit Margin: ADCI's current net profit margins (10.3%) are lower than last year (14.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADCI's earnings have grown by 5.5% per year over the past 5 years.
Accelerating Growth: ADCI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ADCI had negative earnings growth (-7.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (27.9%).
Return on Equity
High ROE: Whilst ADCI's Return on Equity (23.12%) is high, this metric is skewed due to their high level of debt.